

# The functional consequences of sodium channel Na<sub>v</sub>1.8 in human left ventricular hypertrophy

Shakil Ahmad<sup>1,2†</sup>, Petros Tirilomis<sup>2†</sup>, Steffen Pabel<sup>1</sup>, Nataliya Dybkova<sup>2</sup>, Nico Hartmann<sup>2</sup>, Cristina E. Molina<sup>3</sup>, Theodoros Tirilomis<sup>4</sup>, Ingo Kutschka<sup>4</sup>, Norbert Frey<sup>5</sup>, Lars S. Maier<sup>1</sup>, Gerd Hasenfuss<sup>2</sup>, Katrin Streckfuss-Bömeke<sup>2†</sup> and Samuel Sossalla<sup>1,2\*†</sup>

<sup>1</sup>Department of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germany; <sup>2</sup>Department of Cardiology and Pneumology, University Hospital, Georg-August University Goettingen, and DZHK (German Centre for Cardiovascular Research), partner site Goettingen, Goettingen, Germany; <sup>3</sup>Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; <sup>4</sup>Department of Thoracic, Cardiac and Vascular Surgery, University Hospital, Georg-August University Goettingen, Goettingen, Germany; <sup>5</sup>Department of Internal Medicine III, Molecular Cardiology and Angiology, University Medical Center, Schleswig-Holstein, Campus Kiel, Kiel, Germany

## Abstract

**Aims** In hypertrophy and heart failure, the proarrhythmic persistent Na<sup>+</sup> current (I<sub>NaL</sub>) is enhanced. We aimed to investigate the electrophysiological role of neuronal sodium channel Na<sub>v</sub>1.8 in human hypertrophied myocardium.

**Methods and results** Myocardial tissue of 24 patients suffering from symptomatic severe aortic stenosis and concomitant significant afterload-induced hypertrophy with preserved ejection fraction was used and compared with 12 healthy controls. We performed quantitative real-time PCR and western blot and detected a significant up-regulation of Na<sub>v</sub>1.8 mRNA (2.34-fold) and protein expression (1.96-fold) in human hypertrophied myocardium compared with healthy hearts. Interestingly, Na<sub>v</sub>1.5 protein expression was significantly reduced in parallel (0.60-fold). Using whole-cell patch-clamp technique, we found that the prominent I<sub>NaL</sub> was significantly reduced after addition of novel Na<sub>v</sub>1.8-specific blockers either A-803467 (30 nM) or PF-01247324 (1 μM) in human hypertrophic cardiomyocytes. This clearly demonstrates the relevant contribution of Na<sub>v</sub>1.8 to this proarrhythmic current. We observed a significant action potential duration shortening and performed confocal microscopy, demonstrating a 50% decrease in proarrhythmic diastolic sarcoplasmic reticulum (SR)-Ca<sup>2+</sup> leak and SR-Ca<sup>2+</sup> spark frequency after exposure to both Na<sub>v</sub>1.8 inhibitors.

**Conclusions** We show for the first time that the neuronal sodium channel Na<sub>v</sub>1.8 is up-regulated on mRNA and protein level in the human hypertrophied myocardium. Furthermore, inhibition of Na<sub>v</sub>1.8 reduced augmented I<sub>NaL</sub>, abbreviated the action potential duration, and decreased the SR-Ca<sup>2+</sup> leak. The findings of our study suggest that Na<sub>v</sub>1.8 could be a promising antiarrhythmic therapeutic target and merits further investigation.

**Keywords** Left ventricular hypertrophy; Sodium channels; Late sodium current; HFpEF; Arrhythmias; Calcium; SR-Ca<sup>2+</sup> leak

Received: 7 June 2018; Revised: 18 September 2018; Accepted: 10 October 2018

\*Correspondence to: Samuel Sossalla, Department of Internal Medicine II, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.

Tel: +49 551 3963648; Fax: +49 551 398941. Email: samuel.sossalla@ukr.de

†The first two and last two authors contributed equally to the study.

## Introduction

Left ventricular remodelling caused by pressure overload can lead to myocardial hypertrophy. Left ventricular hypertrophy (LVH) is an adaptive response to increased chronic workload and a very common clinical finding.<sup>1,2</sup> It has been reported that LVH can potentially increase the incidents of

congestive heart failure (HF) and sudden cardiac death.<sup>3,4</sup> Furthermore, it has been shown that structural modifications due to LVH are associated with HF with preserved ejection fraction (HFpEF).<sup>5</sup> LVH is also associated with an increased prevalence of cardiac arrhythmias and constitutes an important risk factor for cardiac morbidity and mortality.<sup>6–9</sup> The pathology of LVH shows not only mechanical but also

extensive cellular and molecular remodelling including cardiomyocyte growth changes, dysfunction of excitation–contraction coupling, certain metabolic dysfunctions, and fibrosis.<sup>10,11</sup>

Patients with severe aortic stenosis-dependent symptoms have a tremendous risk of sudden cardiac death if only medically treated.<sup>12</sup> In the past few decades, a great progress has been made in underpinning the cellular and molecular mechanisms of remodelling in myocardial hypertrophy. However, the involvement of voltage-gated sodium channel ( $\text{Na}_v$ ) isoforms in HFpEF and/or myocardial hypertrophy with preserved ejection fraction leading to cardiac arrhythmias has not been elucidated comprehensively. Besides the peak sodium current causing the action potential (AP) upstroke, a small persistent sodium current is existing, also known as late sodium current ( $I_{\text{NaL}}$ ).<sup>13</sup> In case of cardiac pathology, some  $I_{\text{NaL}}$  producing  $\text{Na}_v$  channels reopen or remain active throughout the whole AP. The amplitude of  $I_{\text{NaL}}$  is smaller when compared with peak sodium current but eventually with a larger Na integral due to longer persistence during the course of the AP plateau.<sup>14</sup>  $I_{\text{NaL}}$  has been reported to be enhanced in different clinically relevant cardiac pathologies like hypoxia, ischaemia, and HF.<sup>15–17</sup> In severe myocardial hypertrophy,  $I_{\text{NaL}}$  is also enhanced<sup>18</sup> and may cause intracellular  $\text{Na}^+$  overload and prolongation of the action potential duration (APD).<sup>19</sup> Consequently, the resulting  $\text{Na}^+$  accumulation may lead to intracellular  $\text{Ca}^{2+}$  overload because of reduced efflux and increased influx of  $\text{Ca}^{2+}$  through  $\text{Na}^+/\text{Ca}^{2+}$  exchanger.<sup>20,21</sup>

The voltage-gated sodium channel 1.5 ( $\text{Na}_v1.5$ ) is considered the predominant cardiac  $\text{Na}_v$  isoform in the heart. In the past few years, different reports suggested the existence of other non-cardiac sodium channels including  $\text{Na}_v1.8$  (*SCN10A*) in the heart, which like  $\text{Na}_v1.5$  is tetrodotoxin resistant. In addition, genetic variants of *SCN10A* have been recently shown to influence cardiac conduction.<sup>22,23</sup> Further evidence about  $\text{Na}_v1.8$  in cardiac conduction comes from genome-wide association studies reporting that  $\text{Na}_v1.8$  could modulate cardiac conduction by effecting PR and QRS intervals.<sup>23</sup> However, the expression of  $\text{Na}_v1.8$  in cardiac tissue and its direct involvement in human cardiac arrhythmias is still poorly understood. In the current study, we investigated the presence and the functional role of  $\text{Na}_v1.8$  in cardiac hypertrophy with preserved contractility derived exclusively from patients suffering from severe aortic stenosis. To study the role of  $\text{Na}_v1.8$  channel in the electrophysiological context of human LVH, we used two different  $\text{Na}_v1.8$  blockers, which are described to be very specific for  $\text{Na}_v1.8$  (A-803467 and PF-01247324). The blocker A-803467 is over 100-fold more selective for the  $\text{Na}_v1.8$  channel vs. other human  $\text{Na}_v$  channels.<sup>24</sup> Similarly, the drug PF-01247324 is a highly specific inhibitor of  $\text{Na}_v1.8$  over other  $\text{Na}_v$  channels, even when used at very high concentration.<sup>25</sup>

**Table 1** Patient characteristics: values in the table represent the mean  $\pm$  standard error of the mean

Male sex	50%
Age	66.38 $\pm$ 3.66 years
Ejection fraction	56.95 $\pm$ 1.81%
Dyspnoea	85.7%
Interventricular septum	15.0 $\pm$ 1.7 mm
Aortic valve area	0.8 $\pm$ 0.1 cm <sup>2</sup>
Mean AV pressure gradient	44 $\pm$ 6.4 mm Hg
Diabetes	4.3%
ACE-inhibitors	17.4%
$\beta$ -Blockers	65.2%
Diuretics	76.5%
Digoxin	0.0%
Amiodarone	0.0%
AT1 receptor antagonists	26.1%
Aldosterone antagonists	0.0%
Statins	30.4%
Ca channel blockers	26.1%

ACE, angiotensin-converting enzyme; AT1, angiotensin II receptor-type 1; AV, aortic valve.

## Materials and methods

### Human myocardial tissue

All procedures were conducted in compliance with the local ethics committee. The study conforms to the World Medical Association declaration of Helsinki. Written informed consent was received from all patients prior to inclusion. Myocardial tissue of the hypertrophied left ventricle was obtained from patients ( $n = 24$ ; *Table 1*) with severe aortic valve stenosis and preserved ejection fraction undergoing an open-heart surgery for aortic valve replacement as a classic myectomy (Morrow resection). For molecular purposes, we utilized healthy left ventricular myocardium ( $n = 12$ ) from healthy donor hearts that were not transplanted because of technical reasons.

### Western blots

Myocardial tissue samples from patients with LVH ( $n = 12$ ) compared with healthy control myocardium were homogenized in Tris buffer (pH 7.4) containing Tris–HCl (20 mM), NaCl (200 mM), NaF (20 mM),  $\text{Na}_3\text{VO}_4$  (1 mM), dithiothreitol (1 mM), Triton X-100 (1%), and complete protease and phosphatase inhibitor cocktails (Roche Diagnostics, Germany). Protein concentration was determined by bicinchoninic acid assay (Pierce Biotechnology, United States). Denatured tissue homogenates (10 min, 70°C in 2% beta-mercaptoethanol) were separated on 7.5% sodium dodecyl sulfate–polyacrylamide gels, then transferred to a nitrocellulose membrane, and incubated with the following primary antibodies: mouse monoclonal anti- $\text{Na}_v1.8$  (1:1000, LSBio, United States, LS-C109037), rabbit polyclonal anti- $\text{Na}_v1.5$  (1:2000, Alomone Labs, Israel, ASC-005), and mouse monoclonal anti-GAPDH (1:20000, Biotrend, Germany, BTMC-A473-9) at 4°C overnight.

Secondary antibodies included horseradish peroxidase (HRP)-conjugated goat anti-rabbit and goat anti-mouse (1:10000, Jackson ImmunoResearch, United Kingdom, 111-035-144 and 115-035-062, respectively). The membrane was incubated with secondary antibodies for 1 h at room temperature. Immobilon™ Western Chemiluminescent HRP Substrate (Millipore, Germany) was used for the chemiluminescent detection.

## Quantitative real-time PCR

Human cardiac tissues were snap-frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$ . RNA was isolated by use of the SV Total RNA Isolation System (Promega, Germany). DNA standards were generated by serial dilution in diethyl pyrocarbonate water containing yeast tRNA (30  $\mu\text{L}/\text{mL}$ ) as co-precipitant and used at varying concentrations between 0.125 and 100 000 fg/ $\mu\text{L}$  to ensure exponential growth of DNA amounts in the standard range. One hundred nanogram of RNA was reverse transcribed into cDNA using standard protocols. For quantitative PCR, 10  $\mu\text{L}$  of SYBR Green PCR Master Mix (Thermo Fisher, Germany), 7  $\mu\text{L}$  of nuclease-free water, 1  $\mu\text{L}$  of forward and 1  $\mu\text{L}$  of reverse primer, and 1  $\mu\text{L}$  of cDNA were mixed. Quantitative PCR was carried out using the iQ5 Multicolor Real-time PCR Detection System (Bio-Rad, United States). Forty cycles of 15 s at  $95^{\circ}\text{C}$  followed by 1 min at  $60^{\circ}\text{C}$  were used, and fluorescence was measured after each cycle. After 40 cycles, melt curve analysis was performed to ensure specificity of the products. Threshold cycles were evaluated and normalized to housekeeping genes and controls. The following primer sequences (5'-3') were used for quantitative real-time PCR analyses: SCN10A, forward TGGCAGATGACCTGGAAGAACC and reverse CGATACGGTAGCAAGTCTTGCG (Origene, Cat. no. HP209444, NM\_006514); and GAPDH, forward GTCTCCTCTGA CTCAACAGCG and reverse ACCACCCTGTTGCTGTAGCCAA.

## Myocyte isolation

Left ventricular myocardium was rinsed, cut into small pieces, and incubated at  $37^{\circ}\text{C}$  in a spinner flask filled with Joklik-MEM (JMEM) solution (PAN-Biotech, Germany) that contained 1.0 mg/mL collagenase (Worthington type 1, 185 U/mg, CellSystems, France) and 13% trypsin (Life Technologies, United States). After 45 min, the supernatant was discarded, and fresh JMEM solution containing collagenase was added. The solution was incubated for 10 min until myocytes were disaggregated. The supernatant that contained disaggregated cells was removed and centrifuged (700 rpm, 5 min).

Fresh JMEM with collagenase was added to the remaining tissue. This procedure was repeated four to five times. After every step, the centrifuged cells were resuspended in JMEM solution that contained bovine calf serum 10%, and pH was

adjusted to 7.4 at room temperature. Only cell solutions that contained elongated, not granulated, cardiomyocytes with cross-striations were selected for experiments, plated on laminin-coated recording chambers, and left to settle for 30 min.

## Whole-cell patch clamp

### *I<sub>NaL</sub> measurements*

Ruptured-patch whole-cell voltage-clamp was used to measure  $I_{\text{NaL}}$  in human ventricular cardiomyocytes isolated from hypertrophied hearts with microelectrodes (2–3  $\text{M}\Omega$ ). Pipettes were filled with solution containing CsCl (95 mM), Cs-glutamate (40 mM), NaCl (10 mM),  $\text{MgCl}_2$  (0.92 mM), Mg-ATP (5 mM), Li-GTP (0.3 mM), HEPES (5 mM), niflumic acid (0.03 mM; to block  $\text{Ca}^{2+}$ -activated chloride current), nifedipine (0.02 mM; to block  $\text{Ca}^{2+}$  current), strophanthidin (0.004 mM; to block  $\text{Na}^+/\text{K}^+$ -ATPase), EGTA (1 mM), and  $\text{CaCl}_2$  (0.36 mM; free  $[\text{Ca}^{2+}]_i$ , 100 nM), and pH was adjusted to 7.2 with CsOH. The bath solution contained NaCl (135 mM), tetramethylammonium chloride (5 mM), CsCl (4 mM),  $\text{MgCl}_2$  (2 mM), glucose (10 mM), and HEPES (10 mM), and pH was adjusted to 7.4 with CsOH. To minimize contaminating  $\text{Ca}^{2+}$  currents during  $I_{\text{NaL}}$  measurements,  $\text{Ca}^{2+}$  was omitted from the bath solution. Access resistance was  $<7 \text{ M}\Omega$ . Cardiomyocytes were held at  $-120 \text{ mV}$ , and  $I_{\text{NaL}}$  was elicited using a train of pulses to  $-35 \text{ mV}$  (1000 ms duration, 10 pulses, basic cycle length 2 s). Recordings were initiated 3 min after rupture. The measured  $I_{\text{NaL}}$  at  $-35 \text{ mV}$  was leak subtracted before calculation of the  $I_{\text{NaL}}$  integral (between 100 and 500 ms) and was normalized to membrane capacitance of the measured cell. Cardiomyocytes were treated with either A-803467 (30 nM) or PF-01247324 (1  $\mu\text{M}$ ) for 10 min and compared with the control untreated cells. Measurements were conducted at a temperature of  $37.7^{\circ}\text{C}$ .

### *Action potential duration measurements*

To record the AP from human ventricular cardiomyocytes, the whole-cell patch-clamp technique was used to measure membrane potential (current clamp configuration). Microelectrodes (7–8  $\text{M}\Omega$ ) were filled with solution containing K-Aspartate (92 mM), KCl (48 mM), Mg-ATP (1 mM), HEPES (10 mM), EGTA (0.02 mM), GTP-Tris (0.1 mM), and  $\text{Na}_2\text{-ATP}$  (4 mM), and final pH was adjusted at 7.2 with KOH solution. Bath solution contained NaCl (140 mM), KCl (4 mM),  $\text{MgCl}_2$  (1 mM),  $\text{CaCl}_2$  (2 mM), glucose (10 mM), and HEPES (10 mM), and final pH was adjusted to 7.4 with NaOH. Action potentials were continuously elicited by square current pulses of 1–2 nA amplitude and 1–5 ms duration at increasing stimulation frequency (0.5–3 Hz). Access resistance was typically  $\sim 5\text{--}15 \text{ M}\Omega$  after patch rupture. Fast capacitance was compensated for in a cell-attached configuration. Recordings were commenced after cell stabilization, which was  $\sim 10$  min after rupture. Human cell measurements were

conducted at a temperature of 37.7°C. Every cell was patched and measured before and after drug application.

In all patch-clamp experiments, cardiomyocytes were mounted on the stage of a microscope (Nikon T 300). Fast capacitance was compensated in cell-attached configuration. Membrane capacitance and series resistance were compensated after patch rupture. Signals were filtered with 2.9 and 10 kHz Bessel filters and recorded with an EPC10 amplifier (HEKA Elektronik, Germany).  $\text{Na}_v1.8$  was inhibited using either A-803467 (30 nM for 10 min) or PF-01247324 (1  $\mu\text{M}$  for 5 min). Both drugs were added to the bath solution.

## Measurement of $\text{Ca}^{2+}$ sparks

Isolated cardiomyocytes were incubated at room temperature for 30 min with a Fluo-4 AM loading buffer (10  $\mu\text{M}$ ; Molecular Probes, Life Technologies). Experimental solution contained NaCl (136 mM), KCl (4 mM),  $\text{NaH}_2\text{PO}_4$  (0.33 mM),  $\text{NaHCO}_3$  (4 mM),  $\text{CaCl}_2$  (2 mM),  $\text{MgCl}_2$  (1.6 mM), HEPES (10 mM), and glucose (10 mM), and final pH was adjusted to 7.4 by addition of NaOH solution at room temperature.  $\text{Na}_v1.8$  inhibitors A-803467 (30 nM) and PF-01247324 (1  $\mu\text{M}$ ) were added to their respective groups in the experimental solution.

Cells were continuously superfused during experiments. To wash out the loading buffer and to remove any extracellular dye (as well as to provide enough time for complete de-esterification of Fluo-4 AM), cells were superfused with


experimental solution for 5 min before the experiments were begun.  $\text{Ca}^{2+}$  spark measurements were performed with a laser scanning confocal microscope (LSM 5 Pascal, Zeiss, Germany) using a  $\times 40$  oil-immersion objective. Fluo-4 was excited by an argon ion laser (488 nm), and emitted fluorescence was collected through a 505 nm long-pass mission filter. Fluorescence images were recorded in the line scan mode with 512 pixels per line (width of each scan line: 38.4  $\mu\text{m}$ ) and a pixel time of 0.64  $\mu\text{s}$ . One image consists of 10 000 unidirectional line scans, which equates to a measurement period of 7.68 s. Experiments were conducted at resting conditions after the sarcoplasmic reticulum (SR) was loaded with  $\text{Ca}^{2+}$  by repetitive field stimulation (10 pulses at 1 Hz, 20 V).  $\text{Ca}^{2+}$  sparks were analysed with the program SparkMaster for ImageJ. The mean spark frequency of the respective cell resulted from the number of sparks normalized to cell width and scan rate (100  $\mu\text{m}^{-1} \text{s}^{-1}$ ).

## Results

### Regulation of $\text{Na}_v1.5$ and $\text{Na}_v1.8$ in human left ventricular hypertrophy

To investigate the regulation of  $\text{Na}_v1.8$  and  $\text{Na}_v1.5$  protein expression in human LVH compared with healthy control ventricular myocardium tissue homogenates, western

**Figure 1** Regulation of  $\text{Na}_v1.8$  and  $\text{Na}_v1.5$  expression in hypertrophy. (A) Western blots were performed utilizing left ventricular human tissue homogenates. (B) Densitometry data of  $\text{Na}_v1.8$  and  $\text{Na}_v1.5$  show a significant up-regulation of  $\text{Na}_v1.8$  and down-regulation of  $\text{Na}_v1.5$ . GAPDH was used as an internal loading control in all blots [NF:  $n = 12$ ; and left ventricular hypertrophy (LVH):  $n = 12$ ]. (C) Real-time quantitative PCR showing the relative mRNA expression of  $\text{Na}_v1.8/\text{GAPDH}$  in left ventricle of human NF ( $n = 10$ ) and LVH ( $n = 5$ ).  $*P \leq 0.05$  and  $**P \leq 0.01$  vs. NF. Student's  $t$ -test. Data shown as mean  $\pm$  standard error of the mean and individual values.



blots were performed. We found a significant up-regulation of Nav1.8 protein expression ( $1.96 \pm 0.31$ -fold) in LVH compared with healthy control ventricular myocardium (Figure 1B). In contrast, the expression of Nav1.5 protein was significantly decreased ( $0.60 \pm 0.10$ -fold) compared with Non-failing (NF) (Figure 1B). In accordance to our findings of Nav1.8 expression at the protein level, we recorded a significant up-regulation of Nav1.8 mRNA levels in LVH ( $2.34 \pm 0.64$ -fold,  $n = 5$ ) compared with NF ( $n = 10$ ) by quantitative PCR. The mRNA expression of Nav1.8 is shown as relative expression to the housekeeping gene GAPDH (Figure 1C).

### Nav1.8 contributes to $I_{NaL}$ and action potential duration in human hypertrophy

Given the increased expression of Nav1.8 in human LVH, we investigated the potential contribution to the augmentation of  $I_{NaL}$  and APD prolongation under hypertrophic condition. We adopted the approach using novel-specific blockers of Nav1.8 channel A-803467 and PF-01247324 to inhibit the activity of this channel in human LVH cardiomyocytes for recording  $I_{NaL}$  and APDs by patch clamp. Cardiomyocytes were superfused with either A-803467 or PF-01247324. Our data show a significant reduction in  $I_{NaL}$  (Figure 2) and also shortening of APD<sub>90</sub> (Figure 3) when cardiomyocytes were exposed to Nav1.8 inhibitors compared with the control group. Furthermore, both Nav1.8 inhibitors do not exert any effect on the upstroke velocity and amplitude of the AP (Figure 4A and 4B). Therefore, it can be concluded that Nav1.8 contributes to  $I_{NaL}$  in terms of a positive net inward current to APD prolongation in human hypertrophy.

### Contribution of Nav1.8 to proarrhythmic SR-Ca<sup>2+</sup> leak

During pathological conditions such as HF, an enhanced  $I_{NaL}$  can lead to disturbed SR-Ca<sup>2+</sup> metabolism and hence


potentially proarrhythmic SR-Ca<sup>2+</sup> leakiness. This can give rise to delayed after-depolarizations and thereby arrhythmias. However, the contribution of different Nav isoforms to SR-Ca<sup>2+</sup> leak in human LVH has not been evaluated. Therefore, we measured SR-Ca<sup>2+</sup> leak in isolated cardiomyocytes from human hypertrophied hearts.

We detected a high incident of spontaneous diastolic Ca<sup>2+</sup> release events in hypertrophied cardiomyocytes in the absence of inhibitors (Figure 5A). When cardiomyocytes were incubated with Nav1.8 inhibitors either A-803467 or PF-01247324, a significant decrease in calcium spark frequency (CaSpF) and SR-Ca<sup>2+</sup> leak was observed compared with control group (Figure 5B and 5E). In control cells, CaSpF was  $0.68 \pm 0.12 \mu\text{m}^{-1} \text{s}^{-1}$  ( $n = 145$  cells/12 patients), while in A-806734-treated myocytes, CaSpF was reduced to  $0.27 \pm 0.06 \mu\text{m}^{-1} \text{s}^{-1}$  ( $n = 124$  cells/11 patients,  $P \leq 0.01$ ) and in PF-01247324-treated myocytes to  $0.26 \pm 0.07 \mu\text{m}^{-1} \text{s}^{-1}$  ( $n = 91$  cells/9 patients,  $P \leq 0.01$ ), respectively (Figure 5B). Nav1.8 inhibition with PF-01247324 also resulted in a significant reduction of the Ca<sup>2+</sup> spark duration (Figure 5C), while no differences were recorded for Ca<sup>2+</sup> spark amplitude between control and drug treatment groups (Figure 5D). These data clearly demonstrate the important role of the Nav1.8 channel in SR-Ca<sup>2+</sup> leak regulation in hypertrophy. Taken together, proarrhythmic SR-Ca<sup>2+</sup> release can significantly be decreased by targeting Nav1.8 with specific inhibitors.


## Discussion

LVH is a common clinical finding in daily practice caused, besides some other reason, by hypertension and aortic valve stenosis. At the early stages, myocardial hypertrophy serves as a compensatory mechanism, which can lead to systolic HF at later stages.<sup>26</sup> Importantly, patients with symptomatic aortic stenosis have a tremendous risk of sudden cardiac

**Figure 2** (A) Original traces and (B) data showing individual and mean values  $\pm$  standard error of the mean of  $I_{NaL}$  in human ventricular cardiomyocytes isolated from left ventricular hypertrophy patients (control:  $n = 8$  cells; A-803467:  $n = 7$  cells; PF-01247324:  $n = 7$  cells). \* $P \leq 0.05$ . One-way analysis of variance and Bonferroni's post-test.



**Figure 3** (A) Original action potential recording (0.5 Hz) and (B) data showing individual and mean values  $\pm$  standard error of the mean of APD<sub>90</sub> in left ventricular cardiomyocytes from patients with left ventricular hypertrophy. A-803467 or PF-01247324 paced at 0.5 and 1 Hz ( $n = 5$  cells and  $n = 4$  cells, respectively;  $*P \leq 0.05$  vs. control). Two-way repeated measures analysis of variance and Bonferroni's post-test. All the action potential duration (APD) measurements were performed pairwise by wash-in.




death if only medically treated.<sup>12</sup> In the past few decades, a great progress has been made in underpinning the cellular and molecular mechanisms of remodelling during hypertrophy. However, the mechanistic links between dysregulated proteins and in particular arrhythmogenesis, especially in human hypertrophy, still remain elusive. We herein investigated the regulation of neuronal sodium channel Na<sub>v</sub>1.8 and its role in pathophysiology of human significant hypertrophy. We demonstrate that Na<sub>v</sub>1.8 expression is up-regulated during LVH with preserved ejection fraction compared with healthy left ventricles, while Na<sub>v</sub>1.5 expression is down-regulated in parallel. To the best of our knowledge, this is the first report of such an ion channel switch in human hypertrophy. Furthermore, inhibition of Na<sub>v</sub>1.8 by specific blockers causes a significant reduction of the enhanced I<sub>NaL</sub> and consequently leads to abbreviated APDs in LVH. Moreover, we observed a significant decrease of the proarrhythmic SR-Ca<sup>2+</sup> leak by inhibition of Na<sub>v</sub>1.8 in human hypertrophied cardiomyocytes. Therefore, inhibition of Na<sub>v</sub>1.8 modulates well-accepted proarrhythmogenic triggers such as I<sub>NaL</sub>, APD prolongation, and diastolic SR-Ca<sup>2+</sup> leak.

In the current study, we found increased expression of Na<sub>v</sub>1.8 at both mRNA and protein level in human LVH with preserved contractility when compared with NF. Transcripts of many non-cardiac Na<sub>v</sub> channels (Na<sub>v</sub>1.1, Na<sub>v</sub>1.3, Na<sub>v</sub>1.2, and Na<sub>v</sub>1.6) including Na<sub>v</sub>1.8 were detected in mouse and dog heart, while there was no previous evidence of Na<sub>v</sub>1.8 expression in the human ventricle during LVH.<sup>27,28</sup> Moreover, there have been conflicting reports about the

involvement of these non-cardiac Na<sub>v</sub> isoforms in I<sub>NaL</sub> enhancement in animal models due to species-specific expression. We already reported that the protein expression of other non-cardiac Na<sub>v</sub> channels (Na<sub>v</sub>1.1 and Na<sub>v</sub>1.6) was down-regulated while Na<sub>v</sub>1.5 was increased showing no significant I<sub>NaL</sub> enhancement in a transverse aortic constriction mouse model of compensated hypertrophy.<sup>17</sup> Similar findings were reported in a dog and rat HF model where Na<sub>v</sub>1.5 protein expression was found to be down-regulated, whereas a significant increase in I<sub>NaL</sub> was observed.<sup>29,30</sup> These findings from animal models suggest the involvement of other non-cardiac sodium channels in I<sub>NaL</sub> augmentation and arrhythmogenesis under hypertrophy and HF conditions. However, animal models represent a very artificial variability in hypertrophy, which cannot be compared directly with human hypertrophy with severe aortic stenosis. Moreover, these animal-derived findings cannot be directly translated into the human because of severe differences in cellular electrophysiology. Therefore, the translational data of our current study add novel knowledge on I<sub>NaL</sub> regulation in hypertrophy and show for the first time that I<sub>NaL</sub> augmentation is also caused by over-expression of Na<sub>v</sub>1.8 in human hypertrophy.

Electrophysiological recordings also described that non-cardiac Na<sub>v</sub> channels contribute to I<sub>NaL</sub> up to 44% in canine ventricular cardiomyocytes under normal physiological conditions<sup>31</sup> and Na<sub>v</sub>1.8 was suggested to be a major contributor of I<sub>NaL</sub> in healthy mouse ventricular cardiomyocytes.<sup>32</sup> However, Na<sub>v</sub>1.8 was not investigated before in animal models

**Figure 4** (A) Individual and mean values  $\pm$  standard error of the mean showing upstroke velocity of action potential in control and drug groups from left ventricular hypertrophy cardiomyocytes. (B) Data showing individual and mean values  $\pm$  standard error of the mean of action potential amplitude (APA) measurements from isolated human left ventricular hypertrophy cardiomyocytes. (C) Graph shows the resting membrane potential (RMP) of cardiomyocytes measured under control condition and drug treatments (PF-01247324:  $n = 5$  cells; and A-803467:  $n = 4$  cells). All measurements were performed pairwise by wash-in. Paired Student's *t*-test was performed.




with present heart disease, for example, hypertrophy. It was shown previously by us and other groups that increased  $I_{NaL}$  is implicated as potential contributor to proarrhythmic triggers and thereby to the occurrence of arrhythmias.<sup>33–35</sup> During different pathological conditions associated with heart diseases, over-expression of these non-cardiac Na<sub>v</sub> channels was also shown to be responsible for the prolonged cardiac APD.<sup>31</sup> The functional properties of Na<sub>v</sub>1.8 are characterized by a long AP duration with preserved excitability during sustained stimulation in the dorsal root ganglion.<sup>36</sup> In accordance with an enhanced  $I_{NaL}$ , we observed prolongation of APD in ventricular cardiomyocytes of hypertrophy patients. Inhibition of Na<sub>v</sub>1.8 with specific blockers showed a significant abbreviation of APD. Up-regulated Na<sub>v</sub>1.8 expression in

human hypertrophy may cause increased  $I_{NaL}$  potentially leading to a pathological prolongation of APD in this disease. This prolonged APD can give rise to early after-depolarizations, thereby posing increased fatal risk for ventricular arrhythmias.<sup>13</sup> The partial inhibition of  $I_{NaL}$  up to 50% not only restored healthy APD in failing cardiomyocytes but also ceased after-depolarizations.<sup>13</sup>

Isolated cardiomyocytes from patients with hypertrophic cardiomyopathy showed an augmented  $I_{NaL}$  with a subsequent increase in intracellular Ca<sup>2+</sup> load.<sup>18</sup> Enhanced  $I_{NaL}$  might lead to diastolic Ca<sup>2+</sup> overload through the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger operation in reverse mode.<sup>37</sup> An increase in diastolic Ca<sup>2+</sup> not only results in impaired relaxation but also plays a key role in activating pro-hypertrophic signalling pathways,

**Figure 5** (A) Representative line scan images and (B) calcium spark frequency (CaSpF) in left ventricular cardiomyocytes from patients with left ventricular hypertrophy under control condition and  $\text{Na}_v1.8$  inhibition. Pre-incubation with either A-803467 or PF-01247324 resulted in a significant decrease of CaSpF in hypertrophy compared with control. (C) Mean values of spark duration and (D) spark amplitude of cardiomyocytes. (E) Calculated full  $\text{SR-Ca}^{2+}$  leak in left ventricular cardiomyocytes from left ventricular hypertrophy patients (control:  $n = 145$ ; A-803467:  $n = 124$  cells; PF-01247324:  $n = 91$  cells). Data shown as mean  $\pm$  standard error of the mean. One-way analysis of variance and Bonferroni's post-test. \* $P \leq 0.05$ , \*\* $P \leq 0.01$ .



leading to increased stiffness of the left ventricle.<sup>38,39</sup> These data suggest that  $I_{\text{NaL}}$  is not only the consequence of hypertrophy but is also involved in inducing diastolic intracellular  $\text{Ca}^{2+}$  overload. The resulting  $\text{Ca}^{2+}$  load is thought to trigger intracellular spontaneous  $\text{Ca}^{2+}$ -release events, leading to cytosolic  $\text{Ca}^{2+}$  oscillations, automaticity, and triggered activity. In addition to animal studies, we have previously demonstrated that inhibition of an enhanced  $I_{\text{NaL}}$  with tetrodotoxin or ranolazine reduces the  $\text{SR-Ca}^{2+}$  leak in human diseased cardiomyocytes.<sup>37,40</sup> In the present study, we extend this evidence to human cardiomyocytes with very significant hypertrophy and HFpEF. The highly specific inhibition of  $\text{Na}_v1.8$  potently suppressed the diastolic  $\text{SR-Ca}^{2+}$  leak in ventricular cardiomyocytes of patients with severe LV hypertrophy. Taken together, the data of our present study define a significant contribution of  $\text{Na}_v1.8$  in the initiation of proarrhythmic triggers via  $I_{\text{NaL}}$ -induced  $\text{SR-Ca}^{2+}$  leak and also APD prolongation. The differences between the activation of  $\text{Na}_v1.5$  and  $\text{Na}_v1.8$  suggest that the selective inhibition of  $\text{Na}_v1.8$ -mediated  $I_{\text{NaL}}$  can be antiarrhythmic.

Patients with severe aortic stenosis and concomitant LV hypertrophy including HFpEF are at high risk of sudden cardiac death, and one of the probable causes is lethal arrhythmias. Our current study provides better understanding of electrophysiological disturbances that occur in human severe hypertrophy. We identified a potential new ion channel target ( $\text{Na}_v1.8$ ) and provide a respective possible

pharmacological antiarrhythmic approach. Therefore, these findings provide basic evidence for *in vivo* studies.

## Acknowledgements

We gratefully acknowledge the technical assistance of Timo Schulte, Yvonne Metz, and Johanna Heine.

## Conflict of interest

None declared.

## Funding

S.A. and S.S. are funded by the Marga und Walter Boll-Stiftung through a research grant (project no. 220-12.1-15). K.S.-B. is funded by the Bundesministerium für Bildung und Forschung (BMBF) grant e:Bio—Modul II—Verbundprojekt: CaRNation (031L0075C to K.S.-B. and G.H.). S.S. and L.S.M. are funded by the ReForM-Programme of the University Hospital Regensburg. N.D. and G.H. are funded by the Deutsche Forschungsgemeinschaft (DFG, SFB 1002).

## References

1. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J III, Feinleib M, Castelli WP. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. *Circulation* 1987; 75: I26–I33.
2. Sheridan DJ, Kingsbury MP, Flores NA. Regression of left ventricular hypertrophy; what are appropriate therapeutic



- objectives? *Br J Clin Pharmacol* 1999; **47**: 125–130.
3. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. *Am J Med* 1983; **75**: 4–11.
  4. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 1990; **322**: 1561–1566.
  5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Rev Esp Cardiol (Engl Ed)* 2016; **69**: 1167.
  6. Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. *Am J Cardiol* 1990; **65**: 441–445.
  7. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. *Am J Cardiol* 1987; **60**: 560–565.
  8. Kurdi M, Booz GW. Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC. *J Mol Cell Cardiol* 2011; **50**: 964–971.
  9. Edelmann F. Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction. *ESC Heart Fail* 2015; **2**: 41–45.
  10. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. *Circulation* 2010; **122**: 2727–2735.
  11. DiCarlo LA, Libbus I, Kumar HU, Mittal S, Premchand RK, Amurthur B, KenKnight BH, Ardell JL, Anand IS. Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study. *ESC Heart Fail* 2018; **5**: 95–100.
  12. Ross J Jr, Braunwald E. Aortic stenosis. *Circulation* 1968; **38**: 61–67.
  13. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. *Eur J Heart Fail* 2007; **9**: 219–227.
  14. Antzelevitch C, Nesterenko V, Shryock JC, Rajamani S, Song Y, Belardinelli L. The role of late I Na in development of cardiac arrhythmias. *Handb Exp Pharmacol* 2014; **221**: 137–168.
  15. Despa S, Islam MA, Weber CR, Pogwizd SM, Bers DM. Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged. *Circulation* 2002; **105**: 2543–2548.
  16. Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. *J Physiol* 1996; **497**: 337–347.
  17. Toischer K, Hartmann N, Wagner S, Fischer TH, Herting J, Danner BC, Sag CM, Hund TJ, Mohler PJ, Belardinelli L, Hasenfuss G, Maier LS, Sossalla S. Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. *J Mol Cell Cardiol* 2013; **61**: 111–122.
  18. Coppini R, Ferrantini C, Del LM, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Poggesi C, Cerbai E, Mugelli A, Yao L, Fan P, Belardinelli L, Yacoub M, Olivetto I. Response to letter regarding article, “Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy”. *Circulation* 2013; **128**: e157.
  19. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. *J Pharmacol Exp Ther* 2006; **318**: 214–222.
  20. Pieske B, Maier LS, Piacentino V III, Weisser J, Hasenfuss G, Houser S. Rate dependence of [Na<sup>+</sup>]<sub>i</sub> and contractility in nonfailing and failing human myocardium. *Circulation* 2002; **106**: 447–453.
  21. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L, Maier LS. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts—role of late sodium current and intracellular ion accumulation. *J Mol Cell Cardiol* 2008; **45**: 32–43.
  22. Chambers JC, Zhao J, Terracciano CM, Bezzina CR, Zhang W, Kaba R, Navaratnarajah M, Lotlikar A, Sehmi JS, Kooner MK, Deng G, Siedlecka U, Parasramka S, El-Hamamsy I, Wass MN, Dekker LR, de Jong JS, Sternberg MJ, McKenna W, Severs NJ, de SR, Wilde AA, Anand P, Yacoub M, Scott J, Elliott P, Wood JN, Kooner JS. Genetic variation in SCN10A influences cardiac conduction. *Nat Genet* 2010; **42**: 149–152.
  23. Pfeufer A, van NC, Marcianti KD, Arking DE, Larson MG, Smith AV, Tarasov KV, Muller M, Sotoodehnia N, Sinner MF, Verwoert GC, Li M, Kao WH, Kottgen A, Coresh J, Bis JC, Psaty BM, Rice K, Rotter JI, Rivadeneira F, Hofman A, Kors JA, Stricker BH, Uitterlinden AG, van Duijn CM, Beckmann BM, Sauter W, Gieger C, Lubitz SA, Newton-Cheh C, Wang TJ, Magani JW, Schnabel RB, Chung MK, Barnard J, Smith JD, Van Wagoner DR, Vasani RS, Aspelund T, Eiriksdottir G, Harris TB, Launer LJ, Najjar SS, Lakatta E, Schlessinger D, Uda M, Abecasis GR, Muller-Myhsok B, Ehret GB, Boerwinkle E, Chakravarti A, Soliman EZ, Lunetta KL, Perz S, Wichmann HE, Meitinger T, Levy D, Gudnason V, Ellinor PT, Sanna S, Kaab S, Witteman JC, Alonso A, Benjamin EJ, Heckbert SR. Genome-wide association study of PR interval. *Nat Genet* 2010; **42**: 153–159.
  24. Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krabis M, Liu Y, McGarughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. *Proc Natl Acad Sci U S A* 2007; **104**: 8520–8525.
  25. Payne CE, Brown AR, Theile JW, Loucif AJ, Alexandrou AJ, Fuller MD, Mahoney JH, Antonio BM, Gerlach AC, Printzenhoff DM, Prime RL, Stockbridge G, Kirkup AJ, Bannon AW, England S, Chapman ML, Bagal S, Roeloffs R, Anand U, Anand P, Bungay PJ, Kemp M, Butt RP, Stevens EB. A novel selective and orally bioavailable Nav1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability. *Br J Pharmacol* 2015; **172**: 2654–2670.
  26. Gaasch WH, Delorey DE, St John Sutton MG, Zile MR. Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. *Am J Cardiol* 2008; **102**: 459–462.
  27. Haufe V, Camacho JA, Dumaine R, Gunther B, Bollensdorff C, von Banchet GS, Benndorf K, Zimmer T. Expression pattern of neuronal and skeletal muscle voltage-gated Na<sup>+</sup> channels in the developing mouse heart. *J Physiol* 2005; **564**: 683–696.
  28. Maier SK, Westenbroek RE, Schenkman KA, Feigl EO, Scheuer T, Catterall WA. An unexpected role for brain-type sodium channels in coupling of cell surface depolarization to contraction in the heart. *Proc Natl Acad Sci U S A* 2002; **99**: 4073–4078.
  29. Xi Y, Wu G, Yang L, Han K, Du Y, Wang T, Lei X, Bai X, Ma A. Increased late sodium currents are related to transcription of neuronal isoforms in a pressure-overload model. *Eur J Heart Fail* 2009; **11**: 749–757.
  30. Zicha S, Maltsev VA, Nattel S, Sabbah HN, Undrovinas AI. Post-transcriptional alterations in the expression of cardiac Na<sup>+</sup> channel subunits in chronic heart failure. *J Mol Cell Cardiol* 2004; **37**: 91–100.
  31. Biet M, Barajas-Martinez H, Ton AT, Delabre JF, Morin N, Dumaine R. About half of the late sodium current in cardiac myocytes from dog ventricle is due to non-cardiac-type Na<sup>+</sup> channels. *J Mol Cell Cardiol* 2012; **53**: 593–598.

32. Yang T, Atack TC, Stroud DM, Zhang W, Hall L, Roden DM. Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. *Circ Res* 2012; **111**: 322–332.
33. Maltsev VA, Kyle JW, Mishra S, Undrovinas A. Molecular identity of the late sodium current in adult dog cardiomyocytes identified by Na<sub>v</sub>1.5 antisense inhibition. *Am J Physiol HeartCirc Physiol* 2008; **295**: H667–H676.
34. Shang LL, Pfahnl AE, Sanyal S, Jiao Z, Allen J, Banach K, Fahrenbach J, Weiss D, Taylor WR, Zafari AM, Dudley SC Jr. Human heart failure is associated with abnormal C-terminal splicing variants in the cardiac sodium channel. *Circ Res* 2007; **101**: 1146–1154.
35. Wagner S, Dybkova N, Rasenack EC, Jacobshagen C, Fabritz L, Kirchhof P, Maier SK, Zhang T, Hasenfuss G, Brown JH, Bers DM, Maier LS. Ca<sup>2+</sup>/calmodulin-dependent protein kinase II regulates cardiac Na<sup>+</sup> channels. *J Clin Invest* 2006; **116**: 3127–3138.
36. Patrick HT, Waxman SG. Inactivation properties of sodium channel Na<sub>v</sub>1.8 maintain action potential amplitude in small DRG neurons in the context of depolarization. *Mol Pain* 2007; **3**: 12.
37. Fischer TH, Herting J, Mason FE, Hartmann N, Watanabe S, Nikolaev VO, Sprenger JU, Fan P, Yao L, Popov AF, Danner BC, Schondube F, Belardinelli L, Hasenfuss G, Maier LS, Sossalla S. Late INa increases diastolic SR-Ca<sup>2+</sup>-leak in atrial myocardium by activating PKA and CaMKII. *Cardiovasc Res* 2015; **107**: 184–196.
38. Bers DM. Calcium cycling and signaling in cardiac myocytes. *Annu Rev Physiol* 2008; **70**: 23–49.
39. Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. *J Clin Invest* 2005; **115**: 527–537.
40. Sag CM, Mallwitz A, Wagner S, Hartmann N, Schotola H, Fischer TH, Ungeheuer N, Herting J, Shah AM, Maier LS, Sossalla S, Unsold B. Enhanced late INa induces proarrhythmogenic SR Ca leak in a CaMKII-dependent manner. *J Mol Cell Cardiol* 2014; **76**: 94–105.